Semaglutide: difference between revisions
Diff·revision 16 → 17·22:02, 3 Jan 2025
Difference between revision 16 and revision 17 of Semaglutide. 2 lines changed; the page grew by 75 bytes.
| Revision 16 — 04:56, 20 Dec 2024 ApoB_Aurelio (talk) attribute the mechanism claim to the review rather than stating it flatly 6,658 bytes ±0 | Revision 17 — 22:02, 3 Jan 2025 NewLabNell (talk) expand §Pharmacokinetics 6,733 bytes +75 | ||
|---|---|---|---|
| 19 | }} | 19 | }} |
| 20 | {{hatnote|For the oral formulation and its absorption enhancer, see [[Oral semaglutide]]. For the drug class, see [[GLP-1 receptor agonist]].}} | 20 | {{hatnote|For the oral formulation and its absorption enhancer, see [[Oral semaglutide]]. For the drug class, see [[GLP-1 receptor agonist]].}} |
| + | 21 | {{medical|talk=Scope of the research-material section}} | |
| 21 | 22 | ||
| 22 | '''Semaglutide''' is an acylated analogue of [[Glucagon-like peptide-1]] and a [[GLP-1 receptor agonist]]. Three engineering changes to the native 31-residue sequence give it a circulating half-life of about seven days: α-aminoisobutyric acid at position 8 confers resistance to [[Dipeptidyl peptidase-4]], a C-18 fatty diacid attached at Lys26 confers [[Albumin binding half-life extension|albumin binding]], and an arginine substitution at position 34 leaves a single site available for acylation.{{r|lau2015}} | 23 | '''Semaglutide''' is an acylated analogue of [[Glucagon-like peptide-1]] and a [[GLP-1 receptor agonist]]. Three engineering changes to the native 31-residue sequence give it a circulating half-life of about seven days: α-aminoisobutyric acid at position 8 confers resistance to [[Dipeptidyl peptidase-4]], a C-18 fatty diacid attached at Lys26 confers [[Albumin binding half-life extension|albumin binding]], and an arginine substitution at position 34 leaves a single site available for acylation.{{r|lau2015}} |
| ⋮ | ⋮ | ||
| 64 | * [[Oral semaglutide]] | 65 | * [[Oral semaglutide]] |
| 65 | * [[STEP trial programme]] | 66 | * [[STEP trial programme]] |
| + | 67 | * [[SELECT trial]] | |
| 66 | 68 | ||
| 67 | {{DEFAULTSORT:Semaglutide}} | 69 | {{DEFAULTSORT:Semaglutide}} |